MARKET

BIVI

BIVI

Biovie Inc
NASDAQ
1.270
+0.160
+14.41%
After Hours: 1.350 +0.08 +6.30% 19:57 02/13 EST
OPEN
1.110
PREV CLOSE
1.110
HIGH
1.290
LOW
1.104
VOLUME
232.19K
TURNOVER
--
52 WEEK HIGH
19.50
52 WEEK LOW
1.060
MARKET CAP
9.58M
P/E (TTM)
-0.2473
1D
5D
1M
3M
1Y
5Y
1D
BioVie Announces Its Two Abstracts From Studies On Bezisterim To Treat Alzheimer's Disease, Long COVID Accepted At 2026 American College of Psychiatrists Annual Meeting
Benzinga · 1d ago
BioVie Inc. Announces Phase 2 and 3 Clinical Trials of Bezisterim for Alzheimer's and Long COVID
Reuters · 1d ago
Weekly Report: what happened at BIVI last week (0202-0206)?
Weekly Report · 4d ago
Weekly Report: what happened at BIVI last week (0126-0130)?
Weekly Report · 02/02 09:32
OPTION THERAPEUTICS INC SAYS THINKEQUITY IS THE UNDERWRITER TO IPO
Reuters · 01/26 11:03
Weekly Report: what happened at BIVI last week (0119-0123)?
Weekly Report · 01/26 09:32
Weekly Report: what happened at BIVI last week (0112-0116)?
Weekly Report · 01/19 09:35
Weekly Report: what happened at BIVI last week (0105-0109)?
Weekly Report · 01/12 09:34
More
About BIVI
BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Webull offers BioVie Inc stock information, including NASDAQ: BIVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIVI stock methods without spending real money on the virtual paper trading platform.